153545-97-2

Basic information

• Product Name: Propanoic acid, 2-(4-methylphenoxy)-, methyl ester, (2R)-
• CAS NO: 153545-97-2
• Molecular Formula: C11H14O3
• Molecular Weight: 194.23
• Mol File: 153545-97-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-(4-methylphenoxy)-, methyl ester, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-(4-methylphenoxy)-, methyl ester, (2R)-(153545-97-2)
• EPA Substance Registry System: Propanoic acid, 2-(4-methylphenoxy)-, methyl ester, (2R)-(153545-97-2)

Safety Data

• Hazardous Substances Data: 153545-97-2(Hazardous Substances Data)

Upstream product

• 20047-41-0 methyl (2S)-2-bromopropanoate 
• 1192-96-7 potassium p-cresolate 
• 22504-83-2 2-(4-methylphenoxy)propanoic acid 
• 70044-36-9 ethyl 2-(4-methylphenoxy)propanoate 
• 106-44-5 p-cresol 
• 186581-53-3 diazomethane 
• 14013-55-9 (R)-2-(4-methylphenoxy)propanoic acid 
• 143094-67-1 methyl 2-(4-methylphenoxy)propionate 

Downstream Products

• 14013-55-9 (R)-2-(4-methylphenoxy)propanoic acid 

Relevant articles and documents

N-BENZYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

Enantioselective hydrolysis of some 2-aryloxyalkanoic acid methyl esters and isosteric analogues using a penicillin G acylase-based HPLC monolithic silica column

A technique based on liquid chromatography has been developed to facilitate studies of enantioselectivity in penicillin G acylase (PGA)-catalyzed hydrolysis of some 2-aryloxyalkanoic acid methyl esters and isosteric analogues. PGA was covalently immobilized on an aminopropyl monolithic silica support to create an immobilized HPLC-enzyme reactor. Two sets of experimental data were drawn to calculate the enantioselectivity (E) of the kinetically controlled enantiomer-differentiating reaction, the degree of substrate conversion and the enantiomeric excess of the product. The developed enzymatic reactor was coupled through a switching valve to an achiral analytical column for separation and quantitation of the hydrolysis products. The enantiomeric excess was determined off-line on a PGA-chiral stationary phase. In this way, highly precise E values were determined. A computational study related to the hydrolysis of the considered racemic esters was also carried out in order to unambiguously clarify both the substrate specificity and the enantioselectivity displayed by PGA.